Samsung BiologicsLtd Past Earnings Performance
Past criteria checks 4/6
Samsung BiologicsLtd has been growing earnings at an average annual rate of 31.2%, while the Life Sciences industry saw earnings growing at 23.4% annually. Revenues have been growing at an average rate of 37.9% per year. Samsung BiologicsLtd's return on equity is 10%, and it has net margins of 24.4%.
Key information
31.2%
Earnings growth rate
29.3%
EPS growth rate
Life Sciences Industry Growth | 53.7% |
Revenue growth rate | 37.9% |
Return on equity | 10.0% |
Net Margin | 24.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18Revenue & Expenses Breakdown
How Samsung BiologicsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 4,211,290 | 1,028,404 | 635,566 | 94,672 |
31 Mar 24 | 3,920,570 | 895,298 | 594,082 | 89,436 |
31 Dec 23 | 3,694,589 | 857,691 | 556,931 | 81,588 |
30 Sep 23 | 3,586,607 | 936,917 | 536,774 | 73,717 |
30 Jun 23 | 3,425,675 | 825,714 | 516,685 | 73,036 |
31 Mar 23 | 3,210,913 | 792,869 | 477,864 | 61,653 |
31 Dec 22 | 3,001,295 | 798,056 | 402,863 | 45,884 |
30 Sep 22 | 2,480,082 | 507,465 | 336,062 | 32,308 |
30 Jun 22 | 2,057,774 | 510,074 | 250,420 | 11,874 |
31 Mar 22 | 1,818,513 | 479,557 | 193,338 | 1,911 |
31 Dec 21 | 1,568,007 | 393,589 | 174,488 | 954 |
30 Sep 21 | 1,499,000 | 410,493 | 155,268 | 0 |
30 Jun 21 | 1,322,849 | 334,801 | 137,407 | 0 |
31 Mar 21 | 1,218,377 | 265,297 | 118,074 | 0 |
31 Dec 20 | 1,164,777 | 240,975 | 110,009 | 0 |
30 Sep 20 | 1,102,797 | 355,375 | 92,333 | 0 |
30 Jun 20 | 1,013,033 | 343,437 | 88,094 | 0 |
31 Mar 20 | 783,424 | 278,007 | 90,256 | 0 |
31 Dec 19 | 701,592 | 202,904 | 88,878 | 0 |
30 Sep 19 | 566,539 | 309,564 | 95,192 | 0 |
30 Jun 19 | 482,788 | 238,438 | 91,656 | 0 |
31 Mar 19 | 530,136 | 232,319 | 82,487 | 0 |
31 Dec 18 | 535,806 | 224,109 | 73,169 | 0 |
30 Sep 18 | 523,843 | -103,273 | 60,549 | 0 |
30 Jun 18 | 550,229 | -107,990 | 56,007 | 0 |
31 Mar 18 | 488,016 | -110,558 | 54,007 | 0 |
31 Dec 17 | 464,629 | -96,972 | 54,951 | 0 |
30 Sep 17 | 403,868 | -143,853 | 54,102 | 0 |
30 Jun 17 | 329,199 | -156,259 | 52,581 | 0 |
31 Mar 17 | 313,519 | -184,194 | 51,504 | 0 |
31 Dec 16 | 294,622 | -176,823 | 48,672 | 0 |
30 Sep 16 | 218,108 | 879,382 | 81,043 | 0 |
30 Jun 16 | 194,360 | 1,922,710 | 116,043 | 0 |
31 Mar 16 | 163,426 | 1,933,611 | 136,192 | 0 |
31 Dec 15 | 91,278 | 1,920,179 | 157,937 | 0 |
31 Dec 14 | 105,149 | -95,909 | 89,202 | 187 |
31 Dec 13 | 43,747 | -129,031 | 98,568 | 354 |
Quality Earnings: A207940 has high quality earnings.
Growing Profit Margin: A207940's current net profit margins (24.4%) are higher than last year (24.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A207940's earnings have grown significantly by 31.2% per year over the past 5 years.
Accelerating Growth: A207940's earnings growth over the past year (24.5%) is below its 5-year average (31.2% per year).
Earnings vs Industry: A207940 earnings growth over the past year (24.5%) exceeded the Life Sciences industry 12.9%.
Return on Equity
High ROE: A207940's Return on Equity (10%) is considered low.